Cynosure’s technology seems to have been better at destroying value than it was at destroying fat – Hologic has sold the business for a tenth of the purchase price.
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
GE sells its Biopharma business for $21.4bn, but is its IPO cancelled or merely on hold?
Bain Capital’s investment in a clutch of Pfizer neurology projects raises the question of what interest private equity might have in financing risky biopharma research…
The UK company Midatech Pharma is giving up on speciality drugs to focus on cancer and rare diseases – and it has Novartis in its sights.